Floatz logo

Eb-Dnk101 Dual-Targeting Car-Nk Cells

Metastatic Disease

Beijing BiotechCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

170 Active assets in the Metastatic Disease cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Eb-Dnk101 Dual-Targeting Car-Nk Cells is also rated in:

Unresectable Locally Advanced or Metastatic DiseaseDormant
CC
Indicative ·
47 / 100
View asset →
Unresectable Locally AdvancedDormant
CC
Indicative ·
47 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →